JPH10512617A - Nmr画像形成用の標的磁気標識分子マーカーシステム - Google Patents
Nmr画像形成用の標的磁気標識分子マーカーシステムInfo
- Publication number
- JPH10512617A JPH10512617A JP9517196A JP51719697A JPH10512617A JP H10512617 A JPH10512617 A JP H10512617A JP 9517196 A JP9517196 A JP 9517196A JP 51719697 A JP51719697 A JP 51719697A JP H10512617 A JPH10512617 A JP H10512617A
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- linker
- hydrophobic
- formula
- molecular conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Radiology & Medical Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.疎水性基を備えた磁気応答配位子成分(I)と、選ばれた生物特異的な標的 因子成分(II)が、疎水性基および反応的に官能化された親水性配列を有する両親 媒性ブリッジリンカー成分L(L')によって共に連結して成り、Lと(II)の連結 は共有結合でかつ上記親水性配列の反応性基を含み;およびLと(I)のfで示され る連結は非共有結合でかつ該両成分の疎水性基間の親和力を含み;かつ式(IfL −II)で示されることを特徴とする分子共役結合体システム。 2.常磁性または超常磁性複合成分(I)と、選ばれた生物特異的な標的成分(I I)が、変性両親媒性ブリッジリンカーLによって共に連結して成り、該リンカー は式(i): Y(W−Z−R)m (i) (式中、mは1、2または4; YW部は、成分(I)と非共有結合する疎水性−親油性配列“Y”と親水性−疎 油性配列“W”が共に共有結合してなるセグメント; Zは化学結合または中間連結配列、好ましくはC1〜C4脂肪族セグメント;お よび Rは選ばれた生物活性標的化合物(II)との連結をもたらす結合基である) で示される請求の範囲1に記載の分子共役結合体システム。 3.リンカーL'が、式(ii): L'=(RZWY)2N−A−N(YWZR)2 (ii) (式中、Y,W,ZおよびRは請求の範囲2のLの場合と同意義およびAは疎水 性配列、たとえばYのような配列または脂肪族鎖、好ましくはC2〜C6アルキレ ンであって、但し、式(ii)中の1〜3つのRはHであってもよく、およびリンカ −L'は有効な多官能価を持ち、すなわち、4つ以下の標的単位との連結をもた らしうる) で示される請求の範囲2に記載の分子共役結合体システム。 4.mが4のとき、Yは式: A(Y')4 (式中、AおよびY'は必要に応じてヘテロ原子で中断された、疎水性脂肪族ま たはアリール脂肪族配列である) で示される請求の範囲2に記載の分子共役結合体システム。 5.Aが式:=N(CH2)pN=(ここで、pは2〜6の整数)の基である請求の範 囲3に記載の分子共役結合体システム。 6.Yがポリアルキレンオキシ鎖(ここで、アルキレンは直鎖または分枝鎖C3 〜C8脂肪族単位を示す)から選ばれる請求の範囲1乃至5のいずれか1つに記載 の分子共役結合体システム。 7.疎水性配列Yが、10〜60個のプロピレンオキシ単位を有するポリオキ シプロピレンから選ばれる請求の範囲6に記載の分子共役結合体システム。 8.親水性配列Wがポリオキシメチレンおよびポリオキシエチレンから選ばれ る請求の範囲1乃至5のいずれか1つに記載の分子共役結合体システム。 9.Wが、50〜150個のポリエチレンオキシ単位を有するポリオキシエチ レンから選ばれる請求の範囲8に記載の分子共役結合体システム。 10.Yの相対親油性および疎水性がWの相対親水性および疎油性とほぼ調和し て、HLB値が10〜35の範囲となる請求の範囲1乃至5のいずれか1つに記 載の分子共役結合体システム。 11.YWが、プルロニック、シンペロニック、ポロキサマーのL38、F38 、L42、L44、L61、L62、L62LF、L64、F68、P75、L 81、P85、F108、L121、F127;シンペロニックT−シリーズ;シ ンペロニックL−シリーズ;BRIJ;MYRJ;およびツイーンを含む両親媒性 界面活性剤から選ばれる請求の範囲1乃至5のいずれか1つに記載の分子共役結 合体システム。 12.配位子(I)が常磁性種および磁気次微子から選ばれ、因子(II)が組織およ び表面−特異的ホーミングプロテイン、グリコペプチドおよび炭水化物から選ば れる請求の範囲1乃至5のいずれか1つに記載の分子共役結合体システム。 13.m=2並びにYが48個のプロピレンオキシ単位のポリオキシプロピレン およびWが127個のエチレンオキシ単位のポリエチレンオキシで、WYがプル ロニックF108である請求の範囲1乃至5のいずれか1つに記載の分子共役結 合体システム。 14.(I)がホスファチジン酸で被覆された磁気粒子または疎水性長鎖脂肪酸で 部分エステル化されたポリアミノポリカルボン酸の常磁性金属キレートで構成さ れ、(II)が組織および細胞特異的または表面特異的ホーミングプロテイン、グリ コペプチドおよび炭水化物から選ばれ、およびLがF108(NH2)2、F108 (NHNH2)2、F108(OOC−NHNH2)2、F108(OCH2−CONHN H2)2、F108(OC−NHNH2)2から選ばれる変性シンペロニックである請 求の範囲1乃至5のいずれか1つに記載の分子共役結合体システム。 15.請求の範囲1乃至5のいずれか1つに記載の分子共役結合体システムを製 造する方法であって、適当な親水性および疎水性配列を包含する両親媒性リンカ ーを選択し、次いで(a)該リンカーに変性によって化学的反応性基を付与し、(b) 該反応性基を介して標的因子(II)と共有結合せしめ、および(c)上記疎水性配列 を介して磁気応答化合物と非共有結合せしめることにより、式(IfL−II)の分 子共役結合体システムを得ることを特徴とする分子共役結合体システムの製造法 。 16.工程(b)の後に構造(L−II)の中間体を得、該中間体(L−II)を用いて工 程(c)を行なう請求の範囲15に記載の製造法。 17.工程(c)を工程(b)の前に行なうことによって、工程(c)から中間体(IfL) を得る請求の範囲15に記載の製造法。 18.変性リンカー官能基を、−NH2(またはNHR1、ここでR1は低級アルキ ル)、−CHO(遊離またはジアルキルアセタールの形状)、−CO−NH−NH2 、−O−CO−NH−NH2、−COOH、−SH、−COCl、−O−COCl 等の中から選択する請求の範囲15に記載の製造法。 19.変性リンカーLを、F108(NH2)2、F108(NHNH2)2、F108 (OOC−NHNH2)2、F108(OCH2−CONHNH2)2、F108(OC− NHNH2)2から選択し、(I)をホスファチジン酸で被覆されたマグネタイト次 微子、および疎水化常磁性キレートから選択し、およびIIをビオチン、ラクトー ス、ホレート、および“RGD”ペプチドから選択する請求の範囲15に記載の 製 造法。 20.変性リンカーが、式: で示される請求の範囲15に記載の製造法。 21.請求の範囲12に記載の変性後のリンカー(LおよびL')の用途であって 、官能基Rの反応を介して、標的ベクター(II)と共有結合し、生体の特異的部位 への輸送をもたらすように適当に設計された中間体(L−IIまたはL'−II)を製 造する上記リンカーの用途。 22.変性後のリンカー(LまたはL')の親油性配列と磁気応答配位子(I)の類 似配列との相互の親和力による、上記配位子(I)との結合を経て、中間体(IfL およびIfL')を製造する請求の範囲21に記載の用途。 23.式: (IfL)、(IfL')、(L−II)または(L'−II) (式中、(I),(II),L,L'およびfは請求の範囲1〜4に記載と同意義である) の中間体。 24.Lが請求の範囲1乃至5のいずれか1つに記載のリンカー、およびIが疎 水性基を備えたMRIコントラスト剤である請求の範囲20に記載の構造(IfL )の中間体化合物。 25.Lが、F108(NH2)2、F108(NHNH2)2、F108(OOC−N HNH2)2、F108(OCH2−CONHNH2)2、F108(OC−NHNH2)2 から選ばれ、Iがホスファチジン酸で被覆されたマグネタイト次微子、および疎 水化常磁性キレートから選ばれる請求の範囲24に記載の中間体化合物。 26.ヒトおよび動物患者の体の特異的部位のMRI画像形成に用いる請求の範 囲23乃至25のいずれか1つに記載の化合物。 27.ヒトおよび動物患者の体の特異的部位のMRI画像形成に用いるコントラ スト剤の製造用の、請求の範囲1乃至14のいずれか1つに記載の化合物の用途 。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95810689 | 1995-11-01 | ||
CH95810689.0 | 1995-11-01 | ||
PCT/IB1996/001174 WO1997016474A1 (en) | 1995-11-01 | 1996-10-31 | Targeted magnetically labeled molecular marker systems for the nmr imaging |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10512617A true JPH10512617A (ja) | 1998-12-02 |
JP4018141B2 JP4018141B2 (ja) | 2007-12-05 |
Family
ID=8221811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51719697A Expired - Fee Related JP4018141B2 (ja) | 1995-11-01 | 1996-10-31 | Nmr画像形成用の標的磁気標識分子マーカーシステム |
Country Status (6)
Country | Link |
---|---|
US (1) | US5910300A (ja) |
EP (1) | EP0800545B2 (ja) |
JP (1) | JP4018141B2 (ja) |
AT (1) | ATE243230T1 (ja) |
DE (1) | DE69628731T3 (ja) |
WO (1) | WO1997016474A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006028129A1 (ja) * | 2004-09-10 | 2006-03-16 | Toray Industries, Inc. | 医薬品製剤 |
JP2009542862A (ja) * | 2006-06-29 | 2009-12-03 | インヴィトロジェン ダイナル エーエス | マルチブロックポリマーを含む粒子 |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0800545B2 (en) * | 1995-11-01 | 2011-03-02 | Bracco Research S.A. | Targeted magnetically labeled molecular marker systems for the nmr imaging |
US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
CA2270120A1 (en) | 1996-10-28 | 1998-05-07 | Pal Rongved | Improvements in or relating to diagnostic/therapeutic agents |
US20070036722A1 (en) * | 1996-10-28 | 2007-02-15 | Pal Rongved | Separation processes |
US6331289B1 (en) * | 1996-10-28 | 2001-12-18 | Nycomed Imaging As | Targeted diagnostic/therapeutic agents having more than one different vectors |
US6548663B1 (en) | 1998-03-31 | 2003-04-15 | Bristol-Myers Squibb Pharma Company | Benzodiazepine vitronectin receptor antagonist pharmaceuticals |
BR9909420A (pt) | 1998-03-31 | 2001-09-25 | Du Pont Pharm Co | Composto, kit, composição metalofarmacêutica de diagnóstico ou terapêutica, composição de agente de contraste de ultrassom, composição radiofarmacêutica terapêutica e composição radiofarmacêutica de diagnóstico |
US6524553B2 (en) | 1998-03-31 | 2003-02-25 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
US6794518B1 (en) | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
CN1356913A (zh) | 1998-12-18 | 2002-07-03 | 杜邦药品公司 | 玻连蛋白受体拮抗剂药物 |
US6511649B1 (en) | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
EP1140864A2 (en) | 1998-12-18 | 2001-10-10 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
US6432409B1 (en) * | 1999-09-14 | 2002-08-13 | Antigen Express, Inc. | Hybrid peptides modulate the immune response |
US9289487B2 (en) * | 1999-09-14 | 2016-03-22 | Antigen Express, Inc. | II-key/antigenic epitope hybrid peptide vaccines |
EP2279757A3 (en) | 2000-06-02 | 2011-08-03 | Bracco Suisse SA | Compounds for targeting endothelial cells |
AU2002225878A1 (en) * | 2000-11-02 | 2002-05-15 | Smith Kline Beecham Corporation | Receptor antagonist-lipid conjugates and delivery vehicles containing same |
US20040058458A1 (en) * | 2002-04-18 | 2004-03-25 | The Regents Of The University Of Michigan | Modulated chemical sensors |
US8697029B2 (en) | 2002-04-18 | 2014-04-15 | The Regents Of The University Of Michigan | Modulated physical and chemical sensors |
US7179645B2 (en) * | 2002-09-24 | 2007-02-20 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
EP1556072B1 (en) | 2002-09-17 | 2010-05-19 | Antigen Express, Inc. | Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES |
US7431915B2 (en) | 2003-10-31 | 2008-10-07 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
US7985401B2 (en) | 2003-10-31 | 2011-07-26 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
WO2011008992A2 (en) * | 2009-07-15 | 2011-01-20 | The Regents Of The University Of California | Peptides whose uptake in cells is controllable |
US9695251B2 (en) | 2003-10-31 | 2017-07-04 | The Regents Of The University Of California | Activatable cell penetrating peptides with quenched fluorophores |
US20050260137A1 (en) * | 2004-05-18 | 2005-11-24 | General Electric Company | Contrast agents for magnetic resonance imaging |
EP1996217B1 (en) * | 2006-03-09 | 2010-11-10 | Cambridge Enterprise Limited | Novel antibiotic compositions |
EP2097438B1 (en) * | 2006-12-11 | 2015-08-26 | Bracco Imaging S.p.A | Fibrin binding peptide conjugates for diagnostic and therapeutic applications |
US9068977B2 (en) * | 2007-03-09 | 2015-06-30 | The Regents Of The University Of Michigan | Non-linear rotation rates of remotely driven particles and uses thereof |
JP5707326B2 (ja) * | 2008-09-02 | 2015-04-30 | アンティジェン・エクスプレス・インコーポレーテッドAntigen Express,Inc. | ヒトパピローマウイルス/Ii−keyのハイブリッドおよびその使用方法 |
WO2010088393A2 (en) * | 2009-01-28 | 2010-08-05 | Antigen Express, Inc. | Li-kay hybrid peptides that modulate the immune response to influenza |
US8846331B2 (en) | 2010-08-27 | 2014-09-30 | The Regents Of The University Of Michigan | Asynchronous magnetic bead rotation sensing systems and methods |
WO2012142179A2 (en) | 2011-04-11 | 2012-10-18 | The Regents Of The University Of Michigan | Magnetically induced microspinning for super-detection and super-characterization of biomarkers and live cells |
US9797817B2 (en) | 2012-05-03 | 2017-10-24 | The Regents Of The University Of Michigan | Multi-mode separation for target detection |
WO2014120837A2 (en) | 2013-01-29 | 2014-08-07 | The Regents Of The University Of California | Pretargeted activatable cell penetrating peptide with intracellulary releaseable prodrug |
EA031930B1 (ru) | 2013-01-30 | 2019-03-29 | Авелас Байосайенсиз, Инк. | Молекула селективной доставки для визуализации злокачественной ткани |
US9983110B2 (en) | 2013-11-04 | 2018-05-29 | The Regents Of The University Of Michigan | Asynchronous magnetic bead rotation (AMBR) microviscometer for analysis of analytes |
US10385380B2 (en) | 2014-10-02 | 2019-08-20 | The Regents Of The University Of California | Personalized protease assay to measure protease activity in neoplasms |
US10596259B2 (en) | 2015-05-20 | 2020-03-24 | The Regents Of The University Of California | Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4070246A (en) * | 1976-04-09 | 1978-01-24 | Abbott Laboratories | Reactive matrices |
US4157323A (en) * | 1976-06-09 | 1979-06-05 | California Institute Of Technology | Metal containing polymeric functional microspheres |
US4628037A (en) * | 1983-05-12 | 1986-12-09 | Advanced Magnetics, Inc. | Binding assays employing magnetic particles |
CA1268208A (en) * | 1984-08-10 | 1990-04-24 | Truman Brown | Magnetic micro-particles as contrast agents in nuclear magnetic resonance imaging |
US4762915A (en) * | 1985-01-18 | 1988-08-09 | Liposome Technology, Inc. | Protein-liposome conjugates |
GB8601100D0 (en) * | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
US5271927A (en) * | 1986-02-13 | 1993-12-21 | Celltech Limited | Antibody conjugates with macrocyclic ligands |
US5284646A (en) * | 1986-07-03 | 1994-02-08 | Advanced Magnetics Inc. | Hepatocyte specific receptor mediated endocytosis type magnetic resonance imaging contrast agents |
US5314679A (en) * | 1986-07-03 | 1994-05-24 | Advanced Magnetics Inc. | Vascular magnetic resonance imaging agent comprising nanoparticles |
US4827945A (en) * | 1986-07-03 | 1989-05-09 | Advanced Magnetics, Incorporated | Biologically degradable superparamagnetic materials for use in clinical applications |
US5069216A (en) * | 1986-07-03 | 1991-12-03 | Advanced Magnetics Inc. | Silanized biodegradable super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract |
JPH0720857B2 (ja) * | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
US4986979A (en) * | 1989-03-14 | 1991-01-22 | Neorx Corporation | Imaging tissue sites of inflammation |
NZ233601A (en) * | 1989-05-09 | 1997-06-24 | Gen Hospital Corp | N-terminal acylated peptides having an initial sequence met (or nle) -leu-phe and having a detectable label bound through dtpa or edta to a c-terminal lys or pu residue |
US5395609A (en) * | 1989-06-19 | 1995-03-07 | Antisoma Limited | Synthetic peptides for use in tumor detection |
JP2978187B2 (ja) * | 1989-11-02 | 1999-11-15 | 日本ケミカルリサーチ株式会社 | 修飾スーパーオキサイドディスムターゼの製造法 |
US5552525A (en) * | 1991-02-08 | 1996-09-03 | Diatech Inc. | Technetium-99m labeled peptides for imaging inflammation |
US5370901A (en) * | 1991-02-15 | 1994-12-06 | Bracco International B.V. | Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients |
US5464696A (en) * | 1992-08-13 | 1995-11-07 | Bracco International B.V. | Particles for NMR imaging |
NZ250375A (en) * | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
DE4309333A1 (de) * | 1993-03-17 | 1994-09-22 | Silica Gel Gmbh | Superparamagnetische Teilchen, Verfahren zu ihrer Herstellung und Verwendung derselben |
ATE156706T1 (de) * | 1993-03-17 | 1997-08-15 | Silica Gel Gmbh | Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben |
US5516703A (en) * | 1993-08-20 | 1996-05-14 | The University Of Utah | Coating of hydrophobic surfaces to render them protein resistant while permitting covalent attachment of specific ligands |
EP0800545B2 (en) * | 1995-11-01 | 2011-03-02 | Bracco Research S.A. | Targeted magnetically labeled molecular marker systems for the nmr imaging |
-
1996
- 1996-10-31 EP EP96935209A patent/EP0800545B2/en not_active Expired - Lifetime
- 1996-10-31 AT AT96935209T patent/ATE243230T1/de not_active IP Right Cessation
- 1996-10-31 WO PCT/IB1996/001174 patent/WO1997016474A1/en active IP Right Grant
- 1996-10-31 JP JP51719697A patent/JP4018141B2/ja not_active Expired - Fee Related
- 1996-10-31 US US08/740,620 patent/US5910300A/en not_active Expired - Lifetime
- 1996-10-31 DE DE69628731T patent/DE69628731T3/de not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006028129A1 (ja) * | 2004-09-10 | 2006-03-16 | Toray Industries, Inc. | 医薬品製剤 |
JP2009542862A (ja) * | 2006-06-29 | 2009-12-03 | インヴィトロジェン ダイナル エーエス | マルチブロックポリマーを含む粒子 |
US9738745B2 (en) | 2006-06-29 | 2017-08-22 | Life Technologies As | Particles containing multi-block polymers |
Also Published As
Publication number | Publication date |
---|---|
JP4018141B2 (ja) | 2007-12-05 |
DE69628731D1 (de) | 2003-07-24 |
EP0800545A1 (en) | 1997-10-15 |
US5910300A (en) | 1999-06-08 |
DE69628731T3 (de) | 2012-09-20 |
ATE243230T1 (de) | 2003-07-15 |
EP0800545B1 (en) | 2003-06-18 |
EP0800545B2 (en) | 2011-03-02 |
DE69628731T2 (de) | 2004-04-29 |
WO1997016474A1 (en) | 1997-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10512617A (ja) | Nmr画像形成用の標的磁気標識分子マーカーシステム | |
US6132764A (en) | Targeted polymerized liposome diagnostic and treatment agents | |
Jacques et al. | New classes of MRI contrast agents | |
US5512294A (en) | Targeted polymerized liposome contrast agents | |
JP6170047B2 (ja) | アポトーシス−ターゲティングナノ粒子 | |
US8420055B2 (en) | Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor | |
CA2077670C (en) | Method for enhancing antibody transport through capillary barriers | |
Tiefenauer et al. | In vivo evaluation of magnetite nanoparticles for use as a tumor contrast agent in MRI | |
Zhu et al. | Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes | |
EP2305310A1 (en) | Gold -coated magnetic glyconanoparticles functionalised with proteins for use as diagnostic and therapeutic agents | |
Otis et al. | Dendrimer antibody conjugate to target and image HER-2 overexpressing cancer cells | |
MXPA97002523A (en) | Agents liposomi | |
US20090317327A1 (en) | Aqueous Dispersion of Superparamagnetic Single-Domain Particles, Production and Use Thereof in Diagnosis and Therapy | |
JP2015143262A (ja) | 腫瘍の磁気共鳴画像化法のためのリポソームナノ粒子 | |
JPH10507172A (ja) | リポソーム剤 | |
JP6072205B2 (ja) | 磁気共鳴イメージングのためのガドリニウム発現脂質ナノ粒子 | |
US5352432A (en) | Hepatocyte specific composition and their use as diagnostic imaging agents | |
KR20090119867A (ko) | 산화망간 나노입자를 포함하는 자기공명영상 티1 조영제 | |
EP0361960A2 (en) | Methods and compositions for magnetic resonance imaging | |
DE3701665A1 (de) | Polymer-komplexe, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel | |
JPH10511701A (ja) | 生体組織のnmrイメージングにおける標的コントラスト剤としての磁気標識化学誘引剤 | |
KR101142905B1 (ko) | 양이온성 양친매 고분자를 이용한 양이온성 자성 나노복합체 제조 | |
Kozlowska et al. | Gadolinium-loaded polychelating amphiphilic polymer as an enhanced MRI contrast agent for human multiple myeloma and non Hodgkin's lymphoma (human Burkitt's lymphoma) | |
EP0948361B1 (en) | Magnetic resonance blood pool agents | |
EP1106186A2 (en) | Non-covalent bioconjugates useful for magnetic resonance imaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050315 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050303 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050614 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050801 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050913 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061010 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070109 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070330 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070911 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070920 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100928 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110928 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110928 Year of fee payment: 4 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110928 Year of fee payment: 4 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110928 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120928 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130928 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |